Critical Reviews in Oncology Hematology Critical Reviews in Oncology Hematology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The SWI/SNF complex subunit genes: Their functions, variations, and links to risk and survival outcomes in human cancers
Chromatin remodelling is one of the mechanisms essential in dynamic regulation of gene expression. In mammalians, this is performed by a number of different proteins/protein complexes (Muchardt and Yaniv, 1999). SWI/SNF is one of these complexes that was first identified in yeast when genes affecting the SWItch in mating type (Haber and Garvik, 1977) and Sucrose Non-Fermenting (SNF) phenotypes were identified (Neigeborn and Carlson, 1984). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 24, 2018 Category: Cancer & Oncology Authors: Sevtap Savas, Georgia Skardasi Source Type: research

Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 24, 2018 Category: Cancer & Oncology Source Type: research

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review
Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids. Despite its notable efficacy, bortezomib has side effects like peripheral neuropathy (PNP) with reported incidence of grade ≥3 PNP between 2%–23% Schlafer et al., 2017. Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP. CFZ is already approved for treatment of relapsed and refractory multiple myeloma (RRMM) as single agent as well as in combination with lenalid omide and/or dexamethasone. (Source: Cri...
Source: Critical Reviews in Oncology Hematology - February 24, 2018 Category: Cancer & Oncology Authors: Adeela Mushtaq, Vikas Kapoor, Azka Latif, Ahmad Iftikhar, Umar Zahid, Ali McBride, Ivo Abraham, Irbaz Bin Riaz, Faiz Anwer Source Type: research

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review
Multiple Myeloma (MM) is characterized by monoclonal proliferation of plasma cells in the bone marrow. Based on cytogenetics, disease can be classified as high risk: t(14;16), t(14;20), and/or del (17p13), intermediate risk: t(4;14) and/or (1q) gain, and standard risk: trisomies, t(11;14) and/or t(6;14) (Strite et al., 2015). Consensus based treatment guidelines recommend 4 cycles of induction therapy such as bortezomib, lenalidomide and dexamethasone (VRd) followed by autologous stem cell transplantation therapy (ASCT) in transplant eligible patients with newly diagnosed multiple myeloma (NDMM) (Strite et al., 2015). (Sou...
Source: Critical Reviews in Oncology Hematology - February 24, 2018 Category: Cancer & Oncology Authors: Adeela Mushtaq, Vikas Kapoor, Azka Latif, Ahmad Iftikhar, Umar Zahid, Ali McBride, Ivo Abraham, Irbaz Bin Riaz, Faiz Anwer Source Type: research

Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: a critical review
Radical esophagectomy with extended lymph node dissection is considered the standard of care in treatment of squamous cell carcinoma of esophagus with deep mucosal invasion (pT1a m3) or submucosal involvement (pT1b). However, despite the increasing use of minimally invasive approaches, it remains a major surgery associated with significant morbidities and even mortality risk. Endoscopic resection (ER) results in excellent local control in early superficial mucosal (pT1a) disease yet there is substantial risk of lymph node metastases in T1b disease. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 24, 2018 Category: Cancer & Oncology Authors: Tsz Yeung Kam, Melpomeni Kountouri, Arnaud Roth, Frossard Jean-Loui, Olivier Huber, Stephan M önig, Thomas Zilli Source Type: research

Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 24, 2018 Category: Cancer & Oncology Authors: Joanna Gariani, Olwen Westerland, Sarah Natas, Hema Verma, Gary Cook, Vicky Goh Source Type: research

Hormone replacement therapy in cancer survivors: Utopia?
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 8, 2018 Category: Cancer & Oncology Authors: Angioli Roberto, Daniela Luvero, Armento Grazia, Capriglione Stella, Plotti Francesco, Scaletta Giuseppe, Lopez Salvatore, Montera Roberto, Gatti Alessandra, Serra Giovan Battista, Benedetti Panici Pierluigi, Terranova Corrado Source Type: research

Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature
Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give ...
Source: Critical Reviews in Oncology Hematology - February 8, 2018 Category: Cancer & Oncology Authors: Ombretta Annibali, Mariasanta Napolitano, Giuseppe Avvisati, Sergio Siragusa Source Type: research

Fluoropyrimidine-induced cardiotoxicity
The fluoropyrimidines 5-fluorouracil (5-FU) and capecitabine are antimetabolite drugs, widely used for the treatment of many cancers, including colorectal, breast, and head and neck malignancies. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 7, 2018 Category: Cancer & Oncology Authors: Ilaria Depetris, Donatella Marino, Alessandro Bonzano, Celeste Cagnazzo, Roberto Filippi, Massimo Aglietta, Francesco Leone Source Type: research

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
According to current ESMO – MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent carboplatin-induced emesis, albeit with moderate level of confidence and not unanimous consensus. We performed a meta-analysis of rando mized trials (RCTs) comparing NK1RA + dexamethasone + 5-HT3RA vs. dexamethasone + 5-HT3RA in patients receiving the first cycle of carboplatin-based chemotherapy. Primary outcome was complete response (CR), defined as no emesis and no use of rescue medication. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 7, 2018 Category: Cancer & Oncology Authors: Massimo Di Maio, Chiara Baratelli, Paolo Bironzo, Francesca Vignani, Emilio Bria, Elisa Sperti, Maddalena Marcato, Fausto Roila Source Type: research

Mathematical modeling of cancer metabolism
Systemic approaches are needed and useful for the study of the very complex issue of cancer. Modeling has a central position in these systemic approaches. Metabolic reprogramming is nowadays acknowledged as an essential hallmark of cancer. Mathematical modeling could contribute to a better understanding of cancer metabolic reprogramming and to identify new potential ways of therapeutic intervention. Herein, I review several alternative approaches to metabolic modeling and their current and future impact in oncology. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 7, 2018 Category: Cancer & Oncology Authors: Miguel Ángel Medina Source Type: research

p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: a systematic review and meta-analysis
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 7, 2018 Category: Cancer & Oncology Authors: Yapin Su, Jiuwei Cui, Dongsheng Xu, Mengmeng Wang, Tiankai Xu, Huimn Tian, Fujun Han Source Type: research

Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives
In the last few years, the development of targeted therapies for non-small cell lung cancer (NSCLC) expressing oncogenic driver mutations (e.g. EGFR) has changed the clinical management and the survival outcomes of this specific minority of patients. Several phase III trials demonstrated the superiority of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) over chemotherapy in EGFR-mutant NSCLC patients. However, in the vast majority of cases EGFR TKIs lose their clinical activity within 8 –12 months. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 6, 2018 Category: Cancer & Oncology Authors: Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu Source Type: research

Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: opportunities in cancer therapeutics
Rac1 GTPase signaling pathway has a critical role in the regulation of a plethora of cellular functions governing cancer cell behavior. Recently, it has been shown a critical role of Rac1 in the emergence of resistance mechanisms to cancer therapy. This review describes the current knowledge regarding Rac1 pathway deregulation and its association with chemoresistance, radioresistance, resistance to targeted therapies and immune evasion. This supports the idea that interfering Rac1 signaling pathway could be an interesting approach to tackle cancer resistance. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 4, 2018 Category: Cancer & Oncology Authors: G.A. Cardama, D.F. Alonso, N. Gonzalez, J. Maggio, D.E. Gomez, C. Rolfo, P.Menna Lorenzano Source Type: research

A systematic review of palliative bone radiotherapy based on pain relief and retreatment rates
Palliative radiotherapy has been shown to have effects on Quality of Life during painful bone metastasis. This review aimed to determine equivalence in pain relief (PR) and retreatment rate (RR) using both single and multi-fraction irradiations, based on evaluation of the trial ’s quality. We performed a systematic review since ICRU 50 Report (1993) to June 2017, then evaluated trials for reproducibility and good methodology criteria. We found five studies that were reproducible in both dose and volume prescription. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - February 3, 2018 Category: Cancer & Oncology Authors: Pin Yvan, Paix Adrien, Le F èvre Clara, Antoni Delphine, Blondet Cyrille, Noël Georges Source Type: research